Seguir
Katherine Mendoza, MPH
Katherine Mendoza, MPH
University of Arizona
Dirección de correo verificada de arizona.edu
Título
Citado por
Citado por
Año
Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants dominated era
S Sridhara, AB Gungor, HK Erol, M Al-Obaidi, TT Zangeneh, EJ Bedrick, ...
Plos one 18 (4), e0279326, 2023
92023
Nasal carriage of epidemic methicillin-resistant Staphylococcus aureus 15 (EMRSA-15) clone observed in three Chicago-area long-term care facilities
S Das, CJ Anderson, A Grayes, K Mendoza, M Harazin, DM Schora, ...
Antimicrobial agents and chemotherapy 57 (9), 4551-4553, 2013
92013
Effectiveness of casirivimab-imdevimab and sotrovimab monoclonal antibody treatment among high-risk patients with SARS-CoV-2 infection: a real-world experience
S Murugapandian, AB Gungor, M Al-Obaidi, B Thajudeen, RC Wong, ...
medRxiv, 2022.12. 23.22283921, 2022
12022
Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection
EA Usacheva, LR Peterson, K Mendoza, DM Schora, MM Hossain, JP Jin
Journal of Clinical Medicine Research 11 (2), 98, 2019
12019
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCE (preprint)
B Tanriover, AB Gungor, M Al-Obaidi, B Thajudeen, R Wong, I Mansour, ...
2022
High Prevalence of Multidrug-resistant Organisms: MRSA, VRE, CRE, ESBLs, and C. difficile at a Chicago LTACH
R Barza, K Wyant, P Patel, J Patel, K Mendoza, K Mangold, N Chavez, ...
Open Forum Infectious Diseases 4 (suppl_1), S160-S160, 2017
2017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–6